Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/25/19 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
245 | |
| 10/24/19 | EFFECT | Notice of Effectiveness |
|
1 | |
| 10/24/19 | CERT |
|
1 | ||
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 10/24/19 | S-1MEF | A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1 |
|
7 | |
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
3 | |
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
3 | |
| 10/24/19 | 3 | Initial statement of beneficial ownership of securities |
|
3 |
